Commentary|Articles|November 16, 2026

Benjamin Greenberg, MD, MHS, on Highlights From the 2026 Rare Neuroimmune Disorders Symposium

Listen
0:00 / 0:00

The professor of neurology at UT Southwestern Medical Center discussed emerging trials, proposed changes to myelitis diagnostic criteria and nomenclature, and the unmet needs raised by patients at this year’s symposium.

The Siegel Rare Neuroimmune Association (SRNA) held its 2026 Rare Neuroimmune Disorders Symposium (RNDS) October 15-17, bringing together patients, families, and clinicians for 3 days of sessions on the diagnosis and acute treatment, long-term symptom management, and research of rare neuroimmune disorders.1 The program included updates on diagnostic criteria for transverse myelitis (TM) and neuromyelitis optica spectrum disorder (NMOSD), as well as research presentations on the phase 3 METEOROID trial (NCT05271409) of satralizumab (Enspryng; Genentech) in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).

In METEOROID study, findings showed that satralizumab reduced the risk of relapse by 68% vs placebo (P = .0025), with 87% of treated patients relapse-free at 48 weeks compared with 67% of those on placebo.2,3 In September 2026, the FDA granted priority review to the supplemental biologics license application for satralizumab in MOGAD, with a decision expected by January 10, 2027.3

Benjamin Greenberg, MD, MHS, professor of neurology at UT Southwestern Medical Center, has taken part in the symposium for nearly 2 decades. At this year’s meeting, he co-led a diagnostic workup masterclass, moderated a panel of community members sharing their diagnostic journeys, and presented updates on the Q-Cell Study (NCT03887273), a phase 1 trial evaluating the transplantation of human glial restricted progenitor cells into the spinal cords of patients with TM.1,4

Greenberg has also long advocated for retiring the term “transverse myelitis” in favor of a more etiology-informed nomenclature for inflammatory myelopathies.5 Following the symposium, Greenberg spoke with NeurologyLive® to share the key themes from this year’s RNDS and clinical trials clinicians should watch out for in the future. In the conversation, he also talked about how proposed updates to myelitis diagnostic criteria and nomenclature may reshape care, and the unmet needs, including mental health support, that patients raised at the meeting.

NeurologyLive: What key themes and takeaways from this year’s symposium stood out the most to you?

Benjamin Greenberg, MD, MHS: I always really enjoy this symposium because it’s a great way for a community to get together, and particularly a community of individuals who’ve been affected by rare disorders. Every time we do this, and it’s now going on 20 years, it’s always amazing to meet individuals or families for whom this is the first time they’re meeting somebody else with the same diagnosis. So, it’s very fulfilling in that way. It also gives us an opportunity to hear from patients and families in a very different forum than the clinic about what’s important to them, what their challenges are, and what their needs are, and then hopefully share hopeful information about where we’re going as a field.

It was a jam-packed symposium this year, with a lot of discussions of evolving science and treatments for different conditions. There was a lot of excitement about trials that are either near completion or completed around ways to treat some of these conditions, so I think people came away with a large sense of hope in terms of where we’re going as a field.

Which of the trials discussed at the meeting should clinicians be on the lookout for?

We were able to give a nice update on a stem cell transplant protocol that we have ongoing at UT Southwestern for individuals who’ve been paralyzed or severely affected by myelitis. That’s in its last stages, with the last few enrollments occurring, and we look forward to being able to share the comprehensive data set with the world when it comes to an end.

There were also presentations on preventive therapies. The first-ever registrational trial for the rare disorder anti-MOG associated disorder, or MOGAD, completed and reported its results for a therapy that, at least in the trials, looked to prevent relapses in a statistically significant way. At the symposium, we discussed the fact that this was being submitted to the FDA for review just after the new year, and we hope in the first or early second quarter to be able to hear from the FDA and maybe have the first FDA-approved therapy for this rare disorder on the market.

How do you see the updated diagnostic criteria discussed at the symposium reshaping how neurologists approach suspected rare neuroimmune disorders?

Diagnostic criteria for these conditions have continued to evolve over decades. Recently, we’ve seen new diagnostic criteria for anti-MOG associated disorder and new diagnostic criteria for multiple sclerosis, and we will soon see new diagnostic criteria for NMOSD. All of these were discussed. In addition, new diagnostic criteria and nomenclature for myelitis were presented.

For decades, when patients presented with inflammation in their spinal cord leading to a deficit, they would be diagnosed with transverse myelitis, and that word “transverse” has been stuck to the diagnosis for close to a century. Originally, the word transverse was just meant to describe the plane of inflammation within the spinal cord, that it went transversely across the cord. It has ended up causing dramatic confusion for clinicians and patients alike as to whether transverse myelitis is a standalone diagnosis or part of conditions like multiple sclerosis or NMOSD. Additionally, over the past 20 years, we’ve recognized that a lot of patients who were diagnosed with transverse myelitis actually had other conditions, such as spinal cord strokes or blood flow problems of the cord.

So, committees have now worked for over a year to review all the current data and come up with new diagnostic criteria and nomenclature, so that people know whether they had inflammation of the spinal cord. Importantly, we are dropping the term transverse. What the committee is going to recommend is that individuals be diagnosed as having myelitis, and it is either myelitis due to another condition, like NMOSD or MS, or it is idiopathic myelitis, a myelitis with no known cause. We hope this will help clarify for patients and clinicians alike what category they fit into, and, on the research side, help get homogeneous groups of patients together to be studied appropriately. We hope to have those criteria out over the next year, so sometime in 2027.

It was interesting presenting this to patients and families. One of the concerns that we anticipated, and that was expressed by our partners in the community, was around patient identity. When we change the name, it affects not just patients and families but organizations that have been created with titles such as transverse myelitis. There was concern about what a change in nomenclature would mean for those communities and whether it could inadvertently impact insurance approval or coverage of drugs. So, we had a very open conversation about our efforts to ensure that there are not any unintended consequences from the update. But we are hopeful that, overall, the update will do more good than harm.

What unmet needs were raised at the symposium, and what stood out to you from the panel on patients’ diagnostic journeys?

The unmet needs that continue to be brought up really fall into 3 categories. One is around early recognition and diagnosis, making sure that patients, no matter where they seek care first, have as easy a path as possible to an accurate diagnosis. The second is around restoration of function. Are there ways for us, like through the stem cell transplant or anything else, to repair a nervous system that’s been damaged? The third is around the need for comprehensive care that doesn’t just include medication to prevent relapses, physical and occupational therapy, or symptomatic management.

On one of the panels talking about the diagnostic journey that our patients face, I was struck and humbled by our community members, who very eloquently and openly spoke about their mental health and their needs for support after having such a jarring, unexpected health event from a rare disease that nobody had heard of, one that overturned their existence and changed their personal and professional lives. Multiple of them spoke very well about the need for patients to engage with their health care providers and seek out counseling and support services, but also served as a reminder to practitioners such as myself to be routinely asking how people are doing in a holistic fashion.

It is a critically important unmet need, but one that is so easily met if the conversation occurs. And I shouldn’t say it’s easily met. We do have a problem in our society with access to adequate mental health resources, so even when the need is recognized, it is not easy to get the care we need. But the first step is the recognition. So, I was thrilled to hear those open conversations again and the reminders to all of us that we need to have that conversation.

Is there anything else you’d like to add about this year’s symposium?

After having the privilege of being part of these symposiums now for 20 years, it is incredibly gratifying to see the progress that has been made. The conversations we’re having now are completely different than the conversations we had 20 years ago. The intervention options we have are completely different. And frankly, there are diseases we’re treating now that we didn’t even recognize or diagnose 20 years ago. There was no such thing as anti-MOG associated disorder 20 years ago. So, we’re really in a much better place over these 2 decades for helping guide and manage patients who have these rare disorders.

It’s really happened through the partnership that we have with the community, and the symposium is just one example of that partnership. We say it every year: we learn just as much from our patients and families as we hope they learn from us. It really is a bidirectional exchange. So, it’s always great to do. It’s a lot of work, and my hat’s off to the SRNA every year for putting it together. We always look forward to the next one.

Transcript edited for clarity. Click here for more coverage of MS and demyelinating disorders.

REFERENCES
1. 2026 Rare Neuroimmune Disorders Symposium resource center. Siegel Rare Neuroimmune Association. Accessed November 13, 2026. https://wearesrna.org/resources/2026-rnds
2. Levy M, et al. Safety and Efficacy of Satralizumab in Patients with Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD): Results from the Phase 3 METEOROID Trial. Presented at: 2026 AAN Annual Meeting; April 18-22; Chicago, Illinois.
3. U.S. FDA grants priority review for Roche's enspryng for MOGAD, an autoimmune disease with no approved treatments. News release. Roche. September 9, 2026. Accessed November 13, 2026. https://www.roche.com/media/releases/med-cor-2026-09-10
4. Q study updates: expanded inclusion criteria and what’s next. Siegel Rare Neuroimmune Association. May 18, 2026. Accessed November 13, 2026. https://wearesrna.org/?p=79285
5. Blackburn KM, Greenberg BM. Revisiting Transverse Myelitis: Moving Toward a New Nomenclature. Front Neurol. 2020;11:519468. Published 2020 Sep 23. doi:10.3389/fneur.2020.519468

Related to this article